P/E ratio for Jubilant Pharmova (JUBLPHARMA.NS)
P/E ratio as of April 2024 (TTM): -239
According to Jubilant Pharmova's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -239.052. At the end of 2022 the company had a P/E ratio of 61.8.
P/E ratio history for Jubilant Pharmova from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 61.8 | 276.25% |
| 2021 | 16.4 | 43.61% |
| 2020 | 11.4 | -28.26% |
| 2019 | 16.0 | 19.39% |
| 2018 | 13.4 | -28.79% |
| 2017 | 18.8 | -18.97% |
| 2016 | 23.2 | 51.83% |
| 2015 | 15.3 | -3.94% |
| 2014 | 15.9 | -115.21% |
| 2013 | -104 | 2207.66% |
| 2012 | -4.52 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.